Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: A systematic review and meta-analysis

Circulation: Arrhythmia and Electrophysiology

Volumn 7, Issue 1, 2014, Pages 164-170

  Tan, Vern Hsen ^a,b   Wilton, Stephen B ^a   Kuriachan, Vikas ^a   Sumner, Glen L ^a   Exner, Derek V ^a  

^a LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^b CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Defibrillators; Implantable; Mortality; Review; Shock

Indexed keywords

ARTICLE; BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLASSIFICATION ALGORITHM; COMPARATIVE EFFECTIVENESS; COMPUTER MODEL; EMBASE; FAINTNESS; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MEDICAL INFORMATICS; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SHOCK; SYSTEMATIC REVIEW; THERAPY REDUCTION PROGRAMMING; CARDIOVERSION; EQUIPMENT; EQUIPMENT FAILURE; HEART ARRHYTHMIA; MORTALITY; PROSTHESIS; REVIEW; RISK; RISK ASSESSMENT; RISK FACTOR; SUDDEN CARDIAC DEATH; TREATMENT OUTCOME;

DEFIBRILLATORS, IMPLANTABLE; MORTALITY; REVIEW; SHOCK;

ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; EQUIPMENT FAILURE; HUMANS; ODDS RATIO; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SYNCOPE; TREATMENT OUTCOME;

EID: 84898872436     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.113.001217     Document Type: Article

References (31)

1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346: 877-883.
2. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350: 2140-2150.
3. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352: 225-237.
4. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337: 1576-1583.
5. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, O'Brien B. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101: 1297-1302.
6. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102: 748-754.
7. Sweeney MO, Sakaguchi S, Simons G, Machado C, Connett JE, Yang F; OMNI Study Investigators. Response to the Center for Medicare & Medicaid Services coverage with evidence development request for primary prevention implantable cardioverter-defibrillators: data from the OMNI study. Heart Rhythm. 2012;9: 1058-1066.
8. Volosin KJ, Exner DV, Wathen MS, Sherfesee L, Scinicariello AP, Gillberg JM. Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling. J Cardiovasc Electrophysiol. 2011;22: 280-289.
9. Saxon LA, Hayes DL, Gilliam FR, Heidenreich PA, Day J, Seth M, Meyer TE, Jones PW, Boehmer JP. Long-Term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation. 2010;122: 2359-2367.
10. Sears SF, Todaro JF, Urizar G, Lewis TS, Sirois B, Wallace R, Sotile W, Curtis AB, Conti JB. Assessing the psychosocial impact of the ICD: a national survey of implantable cardioverter defibrillator health care providers. Pacing Clin Electrophysiol. 2000;23: 939-945.
11. Lüderitz B, Jung W, Deister A, Marneros A, Manz M. Patient acceptance of the implantable cardioverter defibrillator in ventricular tachyarrhythmias. Pacing Clin Electrophysiol. 1993;16: 1815-1821.
12. Sears SF, Sowell LD, Kuhl EA, Kovacs AH, Serber ER, Handberg E, Kneipp SM, Zineh I, Conti JB. The ICD shock and stress management program: a randomized trial of psychosocial treatment to optimize quality of life in ICD patients. Pacing Clin Electrophysiol. 2007;30: 858-864.
13. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, Kutalek SP, Friedman PL, Bubien RS, Page RL, Powell J. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105: 589-594.
14. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359: 1009-1017.
15. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, Daubert JP, McNitt S, Andrews ML, Elkin AD; Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Longterm clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110: 3760-3765.
16. Sweeney MO. Point: implantable cardioverter-defibrillator shocks for ventricular tachyarrhythmias increase mortality. Heart Rhythm. 2012;9: 985-987.
17. Dorian P. Counterpoint: implantable cardioverter-defibrillator shocks for ventricular tachyarrhythmias do not increase mortality. Heart Rhythm. 2012;9: 988-991.
18. Swerdlow C, Ellenbogen KA, Klein GJ. Resolving the conflict: implantable cardioverter-defibrillator shocks for ventricular tachyarrhythmias increase mortality. Heart Rhythm. 2012;9: 1328-1330.
19. Ha AH, Ham I, Nair GM, Connolly SJ, Dorian P, Morillo CA, Healey JS. Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm. 2012;9: 2068-2074.
20. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367: 2275-2283.
21. Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A. Effect of long-detection interval vs standard-detection interval for implantable cardioverter- defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013;309: 1903-1911.
22. Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, Alonso J, Nabutovsky Y, Neason C. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol. 2014;25: 52-59.
23. Grimm W. Clinical trials of prophylactic implantable defibrillator therapy in patients with nonischemic cardiomyopathy: what have we learned and what can we expect from future trials? Card Electrophysiol Rev. 2003;7: 463-467.
24. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151: 264-269, W64.
25. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.
26. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM; EMPIRIC Trial Investigators. A comparison of empiric to physician-Tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol. 2006;48: 330-339.
27. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK; PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52: 541-550.
28. Gasparini M, Menozzi C, Proclemer A, Landolina M, Iacopino S, Carboni A, Lombardo E, Regoli F, Biffi M, Burrone V, Denaro A, Boriani G. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: The RELEVANT study. Eur Heart J. 2009;30: 2758-2767.
29. Runsiö M, Kallner A, Källner G, Rosenqvist M, Bergfeldt L. Myocardial injury after electrical therapy for cardiac arrhythmias assessed by troponin-T release. Am J Cardiol. 1997;79: 1241-1245.
30. Pinski SL, Fahy GJ. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation. 1995;92: 1651-1664.
31. Exner DV, Pinski SL, Wyse DG, Renfroe EG, Follmann D, Gold M, Beckman KJ, Coromilas J, Lancaster S, Hallstrom AP. Electrical storm presages nonsudden death the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Circulation. 2001;103: 2066-2071.